Economic Value Of Drugs Should Be Factor In FDA Approval, More Pharma Execs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
PwC Health Research Institute’s survey of 100 senior executives found 43% support FDA use of economic data in deciding whether to approve a drug, up from 14% four years ago.
You may also be interested in...
Reviewing The Reviewers: FDA Divisions Get Mixed Results In BIO Survey
FDA-sponsor interactions vary widely, but more meetings still seem to speed applications; Special Protocol Assessments fall out of favor.
Industry Skeptical Of User Fee Success, PricewaterhouseCoopers Finds
FDA may be wondering whether a lack of praise for its user fee program actually could be a criticism after a survey did not find overwhelmingly agreement the dollars were serving their intended purpose.
Woodcock Faces Maze Of Rules To Become Commissioner Nominee
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: